At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Asthma Control Assessment Via ACT and DRC in Asthmatics Treated With Seretide (50/250) Over 12 Weeks
In Brief
A Phase 4 clinical trial evaluating Salmeterol/Fluticasone 50/250 mcg, Salbutamol 100 mcg, and 1 other intervention for Asthma. Completed, enrolled 221 participants across 32 sites.
Detailed Summary
The majority of asthma patients are not well controlled, despite the availability of asthma medication that could effectively treat the disease. In this study uncontrolled patients who are steroid-naive or on low dose inhaled corticosteroids will be treated with Seretide (salmeterol/fluticasone combination, SFC) 50/250 µg twice daily. The asthma control test (ACT) will be used to detect differences in the level of asthma control during treatment. The study aims to show a correlation between improvements of ACT und the level of asthma control which will be reached by the patients. The aim of the study is to show that most of symptomatic asthma patients can reach 'well controlled asthma' with SFC. We get information about ACT in daily practice and physicians are trained to use the asthma control test as a screening tool and for follow up of asthma management. Correlations are expected between the improvements in ACT, Quality of Life and asthma control according to the Gaining Optimal Asthma controL (GOAL) criteria.
Study Details
Timeline
Interventions
Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.